• Explore /
  • Poster
  • / A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.

A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.

Abstract Video & Slides Poster

Authors

Howard Burris, III

Howard A. Burris III

Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN

Howard A. Burris III , Alexander I. Spira , Matthew H. Taylor , Oladapo O. Yeku , Joyce F. Liu , Pamela N. Munster , Erika P. Hamilton , Jacob Stephen Thomas , Frances Gatlin , Richard T. Penson , Thomas Adam Abrams , Mallika Sachdev Dhawan , Jacqueline M. Walling , John W. Frye , Kevin Romanko , Victoria Sung , Carrie Brachmann , Anthony B. El-Khoueiry

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT03834948

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2516)

DOI

10.1200/JCO.2021.39.15_suppl.2516

Abstract #

2516

Abstract Disclosures

Similar Posters

First Author: Nehal J. Lakhani

First Author: Stéphane Champiat

First Author: John Sarantopoulos

First Author: Sun Young Rha